INCMOR00208
Showing 1 - 5 of 5
Large B-Cell Lymphoma, DLBCL Trial (Tafasitamab, Lenalidomide)
Not yet recruiting
- Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- (no location specified)
Jun 17, 2022
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma Trial in Japan (tafasitamab, lenalidomide, parsaclisib)
Recruiting
- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma
- tafasitamab
- +3 more
-
Aichi, Japan
- +4 more
Jan 24, 2022
Diffuse Large B Cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide)
Recruiting
- Diffuse Large B Cell Lymphoma
-
Dallas, Texas
- +29 more
Jan 20, 2023
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (tafasitamab, parsaclisib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma
-
Birmingham, Alabama
- +49 more
Sep 21, 2022
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (tafasitamab, rituximab, lenalidomide)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- tafasitamab
- +3 more
-
Concord, California
- +255 more
Dec 1, 2022